Alterations in the Gut Microbiome and Suppression of Histone Deacetylases by Resveratrol Are Associated with Attenuation of Colonic Inflammation and Protection Against Colorectal Cancer.

Journal of Clinical Medicine
Haider Rasheed AlrafasPrakash S Nagarkatti

Abstract

Inflammatory bowel disease (IBD) is known to significantly increase the risk for development of colorectal cancer (CRC), suggesting inflammation and cancer development are closely intertwined. Thus, agents that suppress inflammation may prevent the onset of cancer. In the current study, we used resveratrol, an anti-inflammatory stilbenoid, to study the role of microbiota in preventing inflammation-driven CRC. Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development. Gut microbial profile studies demonstrated that resveratrol altered the gut microbiome and short chain fatty acid (SCFA), with modest increases in n-butyric acid and a potential butyrate precursor isobutyric acid. Fecal transfer from resveratrol-treated CRC mice and butyrate supplementation resulted in attenuation of disease and suppression of the inflammatory T cell response. Data also revealed both resveratrol and sodium butyrate (BUT) were capable of inhibiting histone deacetylases (HDACs), correlating with Treg induction. Analysis of The Cancer Genome Atlas...Continue Reading

References

Mar 25, 2010·Cancer Prevention Research·Xiangli CuiLorne J Hofseth
May 4, 2010·Aging·Lorne J HofsethPrakash S Nagarkatti
Apr 2, 2011·International Journal of Ayurveda Research·Manish Kumar GoelJugal Kishore
Jun 28, 2011·Genome Biology·Nicola SegataCurtis Huttenhower
Jun 5, 2013·Nutrition Reviews·Philip B BusbeePrakash S Nagarkatti
Aug 27, 2013·Nature Biotechnology·Morgan G I LangilleCurtis Huttenhower
May 13, 2014·The Journal of Pharmacology and Experimental Therapeutics·Ibrahim AltamemiMitzi Nagarkatti
Jan 13, 2015·Gastroenterology·Mingyang SongAndrew T Chan
Jul 17, 2015·JAMA Oncology·UNKNOWN Global Burden of Disease Cancer CollaborationMohsen Naghavi
Aug 27, 2015·International Journal of Food Sciences and Nutrition·Graziano RiccioniNicolantonio D'Orazio
Nov 26, 2015·The Journal of Nutritional Biochemistry·Hanying ZhangMei-Jun Zhu
Dec 30, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Narendra P SinghMitzi Nagarkatti
Jul 31, 2016·BMC Gastroenterology·Mingming ZhangChenggong Yu
Apr 13, 2017·Nutrition Reviews·Christina M van der BeekKaatje Lenaerts
May 26, 2017·European Journal of Immunology·Kumaraswamy Naidu ChitralaMitzi Nagarkatti
Jul 12, 2017·Molecular Neurobiology·Marcos Roberto de OliveiraJoão Quevedo
Sep 13, 2017·Frontiers in Immunology·Meike KespohlAlexander Visekruna
Sep 25, 2017·Nutrition and Cancer·Álvaro San Hipólito-LuengoConcepción Peiró
Sep 26, 2017·BMJ Open Gastroenterology·Ashley A HibberdYvonne Wettergren

❮ Previous
Next ❯

Datasets Mentioned

BETA
PRJNA528605
PRJNA528631

Methods Mentioned

BETA
flow cytometry
FACS
PCR
PCA

Software Mentioned

Nephele
QIIME FASTQ
GraphPad Prism
Varian MS Workstation
LEfSe
PiCRUSt

Related Concepts

Related Feeds

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.